The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins

Journal of Clinical Investigation

Volumn 117, Issue 3, 2007, Pages 648-658

  Dickey, Chad A ^a,e   Kamal, Adeela ^b   Lundgren, Karen ^b   Klosak, Natalia ^a   Bailey, Rachel M ^a   Dunmore, Judith ^a   Ash, Peter ^a   Shoraka, Sareh ^a   Zlatkovic, Jelena ^a   Eckman, Christopher B ^a   Patterson, Cam ^c   Dickson, Dennis W ^a   Nahman Jr , N Stanley ^d   Hutton, Michael ^a   Burrows, Francis ^b   Petrucelli, Leonard ^a  

^a MAYO CLINIC   (United States)

^b BIOGEN   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; EC 102; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; SERINE; TAU PROTEIN; UBIQUITIN LIGASE CHIP; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG PENETRATION; FEMALE; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; TAUOPATHY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; MICE; MOLECULAR CHAPERONES; PHOSPHORYLATION; PROTEIN FOLDING; RNA, SMALL INTERFERING; SERINE; TAU PROTEINS; TAUOPATHIES; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 33847369469     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29715     Document Type: Article

References (50)

1. Hutton, M., et al. 1998. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 393:702-705.
2. Feany, M.B., and Dickson, D.W. 1996. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann. Neurol. 40:139-148.
3. Gomez-Isla, T., et al. 1997. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41:17-24.
4. Braak, H., and Braak, E. 1991. Neuropathological staging of Alzheimer-related changes. Acta. Neuropathol. (Berl.). 82:239-259.
5. Katsuno, M., et al. 2005. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc. Natl. Acad. Sci. U. S. A. 102:16801-16806.
6. Waza, M., et al. 2006. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J. Mol. Med. 84:635-646.
7. Sahara, N., et al. 2005. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J. Neurochem. 94:1254-1263.
8. Hamos, J.E., et al. 1991. Expression of heat shock proteins in Alzheimer's disease. Neurology. 41:345-350.
9. Perez, N., et al. 1991. Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer's disease. Brain Res. Mol. Brain Res. 11:249-254.
10. Shimura, H., Miura-Shimura, Y., and Kosik, K.S. 2004. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J. Biol. Chem. 279:17957-17962.
11. Petrucelli, L., et al. 2004. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13:703-714.
12. Dickey, C.A., et al. 2006. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phosphoand caspase-3-cleaved tau species. J. Neurosci. 26:6985-6996.
13. Panaretou, B., et al. 1998. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 17:4829-4836.
14. Ciechanover, A., and Brundin, P. 2003. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron. 40:427-446.
15. Kamal, A., et al. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 425:407-410.
16. Dickey, C.A., et al. 2006. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J. 20:753-755.
17. Biamonte, M.A., et al. 2006. Orally active purine-based inhibitors of the heat shock protein 90. J. Med. Chem. 49:817-828.
18. Dickey, C.A., et al. 2005. Development of a high throughput drug screening assay for the detection of changes in tau levels - proof of concept with HSP90 inhibitors. Curr. Alzheimer Res. 2:231-238.
19. Qian, S.B., McDonough, H., Boellmann, F., Cyr, D.M., and Patterson, C. 2006. CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature. 440:551-555.
20. Chang, H.C., Nathan, D.F., and Lindquist, S. 1997. In vivo analysis of the Hsp90 cochaperone Sti1 (p60). Mol. Cell. Biol. 17:318-325.
21. Frydman, J., and Hohfeld, J. 1997. Chaperones get in touch: the Hip-Hop connection. Trends Biochem. Sci. 22:87-92.
22. Chen, S., and Smith, D.F. 1998. Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. J. Biol. Chem. 273:35194-35200.
23. Johnson, B.D., Schumacher, R.J., Ross, E.D., and Toft, D.O. 1998. Hop modulates Hsp70/Hsp90 interactions in protein folding. J. Biol. Chem. 273:3679-3686.
24. Liou, Y.C., et al. 2003. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature. 424:556-561.
25. Grenert, J.P., et al. 1997. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem. 272:23843-23850.
26. Li, T., et al. 2004. Identification of the gene for vitamin K epoxide reductase. Nature. 427:541-544.
27. Soifer, H.S., Zaragoza, A., Peyvan, M., Behlke, M.A., and Rossi, J.J. 2005. A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. Nucleic Acids Res. 33:846-856.
28. Grelle, G., et al. 2006. Identification of VCP/p97, carboxyl terminus of Hsp70-interacting protein (CHIP), and amphiphysin II interaction partners using membrane-based human proteome arrays. Mol. Cell. Proteomics. 5:234-244.
29. Andorfer, C., et al. 2003. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86:582-590.
30. Santacruz, K., et al. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 309:476-481.
31. Tronjanowski, J.Q., and Lee, V.M. 2005. Pathological tau: a loss of normal function or a gain in toxicity? Nat. Neurosci. 8:1136-1137.
32. Kobayashi, S., et al. 1993. A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule. FEBS Lett. 335:171-175.
33. Hong, M., and Lee, V.M. 1997. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J. Biol. Chem. 272:19547-19553.
34. Barrachina, M., Maes, T., Buesa, C., and Ferrer, I. 2006. Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 32:505-516.
35. Cohen, E., Bieschke, J., Perciavalle, R.M., Kelly, J.W., and Dillin, A. 2006. Opposing activities protect against age-onset proteotoxicity. Science. 313:1604-1610.
36. Goldberg, A.L., Stein, R., and Adams, J. 1995. New insights into proteasome function: from archaebacteria to drug development. Chem. Biol. 2:503-508.
37. Dalton, W.S. 2004. The proteasome. Semin. Oncol. 31(Suppl. 16):3-9; discussion 33.
38. Dai, Q., et al. 2003. CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J. 22:5446-5458.
39. Grenert, J.P., Johnson, B.D., and Toft, D.O. 1999. The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes. J. Biol. Chem. 274:17525-17533.
40. Connell, P., et al. 2001. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 3:93-96.
41. Weaver, C.L., Espinoza, M., Kress, Y., and Davies, P. 2000. Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol. Aging. 21:719-727.
42. Ghoshal, N., et al. 2001. Tau-66: evidence for a novel tau conformation in Alzheimer's disease. J. Neurochem. 77:1372-1385.
43. Cripps, D., et al. 2006. Alzheimer's disease-specific conformation of hyperphosphorylated phf-tau is polyubiquitinated through lys-48, lys-11, and lys-6 ubiquitin conjugation. J. Biol. Chem. 281:10825-10838.
44. Reynolds, M.R., Berry, R.W., and Binder, L.I. 2005. Site-specific nitration differentially influences tau assembly in vitro. Biochemistry. 44:13997-14009.
45. Biernat, J., et al. 2002. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol. Biol. Cell. 13:4013-4028.
46. Mandelkow, E.M. 2006. The modes and pathways of Tau's toxicity to neurons in neurodegeneration. Paper presented at the Keystone Symposia Conference on Alzheimer's Disease: Genes, Cellular Pathways and Therapies. February 21-26. Breckenridge, Colorado, USA.
47. Sittler, A., et al. 2001. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10:1307-1315.
48. Waza, M., et al. 2005. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11:1088-1095.
49. Petrucelli, L., and Dawson, T.M. 2004. Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann. Med. 36:315-320.
50. Castro, J.E., et al. 2005. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood. 106:2506-2512.